Timothy C. Rodell

1.7k total citations
36 papers, 1.2k citations indexed

About

Timothy C. Rodell is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Timothy C. Rodell has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 11 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Timothy C. Rodell's work include Hepatitis C virus research (7 papers), Cancer Research and Treatments (6 papers) and Immunotherapy and Immune Responses (5 papers). Timothy C. Rodell is often cited by papers focused on Hepatitis C virus research (7 papers), Cancer Research and Treatments (6 papers) and Immunotherapy and Immune Responses (5 papers). Timothy C. Rodell collaborates with scholars based in United States, Singapore and Spain. Timothy C. Rodell's co-authors include Yingnian Lu, Alex Franzusoff, Richard C. Duke, John C. Cheronis, John E. Repine, David Apelian, John G. McHutchison, Thomas H. King, Anuj Gaggar and G. Mani Subramanian and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Timothy C. Rodell

36 papers receiving 1.2k citations

Peers

Timothy C. Rodell
Shaogui Wan China
Masumi Shimizu Japan
Sören T. Eichhorst Germany
Motomi Yamazaki Japan
Nadine Weich United States
T Hayakawa Japan
Pushpa Hegde France
Liyun Zou China
Thomas Whisenant United States
Shaogui Wan China
Timothy C. Rodell
Citations per year, relative to Timothy C. Rodell Timothy C. Rodell (= 1×) peers Shaogui Wan

Countries citing papers authored by Timothy C. Rodell

Since Specialization
Citations

This map shows the geographic impact of Timothy C. Rodell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy C. Rodell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy C. Rodell more than expected).

Fields of papers citing papers by Timothy C. Rodell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy C. Rodell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy C. Rodell. The network helps show where Timothy C. Rodell may publish in the future.

Co-authorship network of co-authors of Timothy C. Rodell

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy C. Rodell. A scholar is included among the top collaborators of Timothy C. Rodell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy C. Rodell. Timothy C. Rodell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Muscarella, Peter, Tanios Bekaii‐Saab, Kristi McIntyre, et al.. (2021). A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. SHILAP Revista de lepidopterología. 7(1). 8–19. 17 indexed citations
2.
Lok, Anna S., Calvin Q. Pan, Steven-Huy Han, et al.. (2016). Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. Journal of Hepatology. 65(3). 509–516. 141 indexed citations
3.
Heery, Christopher R., Myrna Rauckhorst, Jennifer L. Marté, et al.. (2015). Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunology Research. 3(11). 1248–1256. 104 indexed citations
4.
Gaggar, Anuj, Claire Coeshott, David Apelian, et al.. (2014). Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study. Vaccine. 32(39). 4925–4931. 80 indexed citations
5.
6.
Tucker, Jo A., Caroline Jochéms, Benjamin Boyerinas, et al.. (2014). Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer Immunology Immunotherapy. 63(12). 1307–1317. 19 indexed citations
7.
Donahue, Renee N., Italia Grenga, Lauren M. Lepone, et al.. (2014). Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301). Journal for ImmunoTherapy of Cancer. 2(S3). 3 indexed citations
8.
Richards, Donald, Peter Muscarella, Tanios Bekaii‐Saab, et al.. (2014). Abstract 5314: A proteomic signature predicts response to a therapeutic vaccine in pancreas cancer; analysis from the GI-4000-02 trial. Cancer Research. 74(19_Supplement). 5314–5314. 2 indexed citations
9.
10.
McHutchison, John G., Gregory T. Everson, Ira M. Jacobson, et al.. (2010). 277 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES BIOPSY NECRO-INFLAMMATORY SCORES AND ALT NORMALIZATION AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV PATIENTS. Journal of Hepatology. 52. S116–S116. 3 indexed citations
11.
Hockenbery, David M., Scott Cruickshank, Timothy C. Rodell, et al.. (2007). A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 109(10). 4557–4563. 79 indexed citations
12.
McDonald, George B., Scott Cruickshank, Timothy C. Rodell, & David M. Hockenbery. (2006). Oral beclomethasone dipropionate (BDP) for gastrointestinal GVHD: A corticosteroid-sparing treatment with improved survival at day +200. Biology of Blood and Marrow Transplantation. 12(2). 1–2. 2 indexed citations
13.
Haller, Aurelia A., Georg M. Lauer, Thomas H. King, et al.. (2006). Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 25(8). 1452–1463. 92 indexed citations
14.
Franzusoff, Alex, Richard C. Duke, Thomas H. King, Yingnian Lu, & Timothy C. Rodell. (2005). Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opinion on Biological Therapy. 5(4). 565–575. 52 indexed citations
15.
Narotam, Pradeep K., et al.. (1998). Traumatic Brain Contusions: A Clinical Role for the Kinin Antagonist CP-0127. Acta Neurochirurgica. 140(8). 793–803. 34 indexed citations
16.
Rodell, Timothy C.. (1996). The kallikrein/kinin system and kinin antagonists in trauma. Immunopharmacology. 33(1-3). 279–283. 24 indexed citations
17.
Rodell, Timothy C., Linda A. Scharschmidt, & W. A. Knaus. (1995). 195 RESULTS OF A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CP-0127, A NOVEL BRADYKININ ANTAGONIST. IN PATIENTS WITH SIRS AND SEPSIS. Shock. 3(5). 60–60. 4 indexed citations
18.
Rodell, Timothy C., et al.. (1995). Role of Kinins in Inflammatory Responses. Clinical Immunotherapeutics. 3(5). 352–361. 12 indexed citations
19.
Rodell, Timothy C., John C. Cheronis, & John E. Repine. (1988). Endothelial Cell Xanthine Oxidase-derived Toxic Oxygen Metabolites Contribute to Acute Lung Injury from Neutrophil Elastase. CHEST Journal. 93(3). 146S–146S. 16 indexed citations
20.
Repine, John E., John C. Cheronis, Timothy C. Rodell, Stuart L. Linas, & Anita Patt. (1987). Pulmonary Oxygen Toxicity and Ischemia-Reperfusion Injury: A Mechanism in Common Involving Xanthine Oxidase and Neutrophils. American Review of Respiratory Disease. 136(2). 483–485. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shaogui Wan Breakdown of academic impact, for papers by Masumi Shimizu Breakdown of academic impact, for papers by Sören T. Eichhorst Breakdown of academic impact, for papers by Motomi Yamazaki Breakdown of academic impact, for papers by Nadine Weich Breakdown of academic impact, for papers by T Hayakawa Breakdown of academic impact, for papers by Pushpa Hegde Breakdown of academic impact, for papers by Liyun Zou Breakdown of academic impact, for papers by Thomas Whisenant
Rankless by CCL
2026